ALGS (Aligos Therapeutics, Inc.) Stock Financials & Earnings

ALGSAligos Therapeutics, Inc.

Mkt Cap$45M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$2M

Net Income (TTM)-$24M

EPS (TTM)-$8.59

Free Cash Flow (TTM)-$83M

Gross Margin76.4%

Op. Margin-4024.9%

Net Margin-1106.7%

FCF Margin-3794.1%

P/S Ratio (TTM)20.7x

P/E Ratio (TTM)—

YoY Rev Growth-44.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$3M	$3M	-$24M
Q2 23	$7M	$7M	-$19M
Q3 23	$3M	$3M	-$19M
Q4 23	$3M	$3M	-$26M
Q1 24	$986K	$986K	-$22M
Q2 24	$1M	$451K	-$26M
Q3 24	$1M	$1M	-$20M
Q4 24	$629K	$629K	-$21M
Q1 25	$311K	$311K	-$19M
Q2 25	$965K	$706K	-$19M
Q3 25	$741K	$741K	-$28M
Q4 25	$169K	-$88K	-$22M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$18M	$9M	—
Q2 23	$17M	$9M	—
Q3 23	$16M	$6M	—
Q4 23	$22M	$6M	—
Q1 24	$16M	$7M	—
Q2 24	$21M	$6M	—
Q3 24	$17M	$5M	—
Q4 24	$16M	$5M	—
Q1 25	$15M	$5M	—
Q2 25	$14M	$6M	—
Q3 25	$24M	$5M	—
Q4 25	$17M	—	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$79M	$25M	$104M
Q2 23	$91M	$10K	$91M
Q3 23	$70M	$0	$70M
Q4 23	$136M	$0	$136M
Q1 24	$24M	$89M	$113M
Q2 24	$45M	$49M	$95M
Q3 24	$35M	$40M	$75M
Q4 24	$37M	$20M	$57M
Q1 25	$74M	$64M	$138M
Q2 25	$19M	$104M	$123M
Q3 25	$42M	$57M	$99M
Q4 25	$18M	$60M	$78M

Shares Outstanding

Revenue Per Employee

Revenue / Employee